Press Releases

MISSISSAUGA, ON, July 31, 2019 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced it intends to release its second quarter 2019 financial results before markets open on Wednesday, August 14

GERMANTOWN, Md., July 31, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR) ("Neuralstem" or the "Company") today announced the closing of its underwritten public offering of an aggregate of 2,777,777 units at a public offering price of $2.70 per unit resulting in  gross proceeds of approximately $7,500,000

NEW HAVEN, Conn., July 31, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or the "Company"), a clinical stage biopharmaceutical company with a portfolio of late-stage product candidates for neurological and neuropsychiatric diseases, announced today that it enrolled the first patient in a Phase 3 clinical trial to evaluate the

SAN DIEGO, July 31, 2019 /PRNewswire/ -- Mesa Biotech Inc. is a privately-held, molecular diagnostic company that has developed the Accula™ System, an affordable, sample-to-answer, CLIA-waived PCR (polymerase chain reaction) testing platform designed specifically for point-of-care (POC) infectious disease diagnosis. Today, Mesa Biot

COLTS NECK, N.J., July 31, 2019 /PRNewswire/ -- Retro Fitness, a leader in the high value, low price fitness space is excited to announce the appointment of Andrew Alfano as CEO. With more than 25 years in retail and franchising, he has built leading teams to drive customer experience, product innovation and brand expansion. Alfano jo

VAUGHAN, ON, July 31, 2019 /PRNewswire/ - CannTrust Holdings Inc. ("CannTrust" or the "Company", TSX: TRST, NYSE: CTST) today announced that the special committee (the "Special Committee") of the Company's board of directors has retained Greenhill & Co. Canada Ltd. as the Special Committee's financial advisor, to assist in a review of strategic alternatives. Th

LUND, Sweden, July 31, 2019 /PRNewswire/ -- BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) today announces that Pfizer Inc. ("Pfizer") (NYSE: PFE) has selected the first target under the companies' cancer immunotherapy research collaboration and license

ROCKVILLE, Md., July 31, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, today announced it entered into a license agreement with Pfizer Inc.Under the terms of the agreement, REGENXB

DUBLIN, July 31, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the second quarter ended June 30, 2019. Revenue for the second quarter of 2019 was $26.2 million. Second quarter operating loss was

MDNA19 demonstrates robust efficacy and safety with or without checkpoint inhibitors in preclinical models; Clinical studies expected to commence in 2020 TORONTO and HOUSTON, July 31, 2019 /PRNewswire/ - Medicenna Therapeutics Corp.  ("Medicenna" or "the Company") (TSX: MDNA, OTCQB: